Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension

被引：0
|
作者：
Thaci, Diamant [1 ]
Puig, Luis [2 ]
Merola, Joseph F. [3 ]
Jullien, Denis [4 ]
Costanzo, Antonio [5 ]
Wang, Maggie [6 ]
Deherder, Delphine [7 ]
Lopez Pinto, Jose M. [8 ]
Lebwohl, Mark [9 ]
机构：
[1] Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Schleswig Holst, Germany
[2] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain
[3] UT Southwestern Med Ctr, Dallas, TX USA
[4] Univ Lyon, Hosp Civils Lyon, Dept Dermatol, Hop Edouard Herriot, Lyon, France
[5] IRCCS, Dept Dermatol, Humanitas Clin & Res Ctr, Milan, Italy
[6] UCB Pharma, Morrisville, NC USA
[7] UCB Pharma, Braine Lalleud, Belgium
[8] UCB Pharma, Madrid, Spain
[9] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2024年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2348
引用
收藏
页码：4733 / 4735
页数：3
相关论文
共 50 条
  • [21] Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease With 3 Years of Treatment: Results From the FORTIFY Open-Label Long-Term Extension
    Ferrante, M.
    Panaccione, R.
    Colombel, J. F.
    Dubinsky, M. C.
    Hisamatsu, T.
    Lindsay, J. O.
    Song, A.
    Yao, Y.
    Zhang, Y.
    Zambrano, J.
    Aponte, F.
    Duan, W. R.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i109 - i111
  • [22] Long-term efficacy and safety of risankizumab (RZB) for the treatment of moderate to-severe plaque psoriasis: Interim analysis of results from the LIMMitless open-label extension trial beyond 4 years of follow-up
    Papp, Kim A.
    Lebwohl, Mark G.
    Puig, Lluis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB77 - AB77
  • [23] Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term Extension
    Ferrante, M.
    Panaccione, R.
    Colombel, J. F.
    Dubinsky, M.
    Hisamatsu, T.
    Lindsay, J. O.
    Song, A.
    Neimark, E.
    Zhang, Y.
    Kligys, K.
    Crowley, J.
    Duan, W. R.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I167 - I169
  • [24] Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study
    Wallace, D. J.
    Hobbs, K.
    Clowse, M. E. B.
    Petri, M.
    Strand, V.
    Pike, M.
    Merrill, J. T.
    Leszczynski, P.
    Neuwelt, C. M.
    Jeka, S.
    Houssiau, F.
    Keiserman, M.
    Ordi-Ros, J.
    Bongardt, S.
    Kilgallen, B.
    Galateanu, C.
    Kalunian, K.
    Furie, R.
    Gordon, C.
    ARTHRITIS CARE & RESEARCH, 2016, 68 (04) : 534 - 543
  • [25] Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
    Deleuran, Mette
    Thaci, Diamant
    Beck, Lisa A.
    de Bruin-Weller, Marjolein
    Blauvelt, Andrew
    Forman, Seth
    Bissonnette, Robert
    Reich, Kristian
    Soong, Weily
    Hussain, Iftikhar
    Foley, Peter
    Hide, Michihiro
    Bouaziz, Jean-David
    Gelfand, Joel M.
    Sher, Lawrence
    Schuttelaar, Marie L. A.
    Wang, Chen
    Chen, Zhen
    Akinlade, Bolanle
    Gadkari, Abhijit
    Eckert, Laurent
    Davis, John D.
    Rajadhyaksha, Manoj
    Staudinger, Heribert
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (02) : 377 - 388
  • [26] Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis
    Lebwohl, Mark G.
    Sugarman, Jeffrey L.
    Gold, Linda Stein
    Pariser, David M.
    Lin, Tina
    Pillai, Radhakrishnan
    Martin, Gina
    Harris, Susan
    Israel, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (01) : 282 - 285
  • [27] Long-term Safety and Efficacy of Risankizumab for the Treatment of Moderate to-Severe Plaque Psoriasis: Interim Analysis of Results From the LIMMitless Open-label Extension Trial Up to 5 Years of Follow-up
    Papp, Kim A.
    Lebwohl, Mark G.
    Puig, Lluis
    Ohtsuki, Mamitaro
    Beissert, Stefan
    Liu, Jie
    Wu, Tianshuang
    Sinvhal, Ranjeeta
    Soliman, Ahmed M.
    Chen, Michael M.
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB62 - AB62
  • [28] Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up
    Papp, K. A.
    Lebwohl, M. G.
    Puig, L.
    Ohtsuki, M.
    Beissert, S.
    Zeng, J.
    Rubant, S.
    Sinvhal, R.
    Zhao, Y.
    Soliman, A. M.
    Alperovich, G.
    Leonardi, C.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (06) : 1135 - 1145
  • [29] Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
    Mark G. Lebwohl
    Andrew Blauvelt
    Alan Menter
    Kim A. Papp
    Scott Guenthner
    Radhakrishnan Pillai
    Robert J. Israel
    Abby Jacobson
    American Journal of Clinical Dermatology, 2019, 20 : 863 - 871
  • [30] Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
    Lebwohl, Mark G.
    Blauvelt, Andrew
    Menter, Alan
    Papp, Kim A.
    Guenthner, Scott
    Pillai, Radhakrishnan
    Israel, Robert J.
    Jacobson, Abby
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2019, 20 (06) : 863 - 871
12345